COVID-19 Resources > COVID-19 Web Series FAQs > NSAIDs, ACEI, ARBs, and Remdesivir

ACMT COVID-19 Web Series FAQs

NSAIDs, ACEI, ARBs, and Remdesivir

The presence of risk factors for more severe disease and worse outcome from COVID-19 has resulted in many statements over the last few months regarding the potential role of medications in both aggravating the disease and facilitating recovery.

Conflicting recommendations regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the anti-hypertensive and cardio- and renal-protective drug classes (Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blocking (ARB) drugs) in patients with underlying hypertension, heart disease and diabetes mellitus serves as an important warning about rushing to judgment based on conflating “association” and “causation”, and highlights problems with over-interpreting basic science or animal experimental data in application to human disease.

Similar problems arose with the rush to use chloroquine or hydroxychloroquine (click HERE for the webinar, click HERE for FAQs), where basic science rationale for these drugs’ potential utility did not incorporate adequate precautions regarding the presence of polypharmacy and the risk of QTc prolongation in human patients – cell cultures don’t have a cardiac conduction system, but people do!

The ACMT COVID-19 webinar of April 1, 2020 provides a quick look at the role of the cell-bound ACE2 receptor in SARS-CoV-2 binding (via the viral S protein), and briefly discusses the available data for the anti-viral, remdesivir. The following FAQs are provided to supplement these webinars and will be updated as more information becomes available.

 

FAQs - Theoretical and experimental issues regarding COVID-19 and ACE receptors

Updated: May 13, 2020
 Are ACE2 receptors the “final common pathway” for COVID-19 viral entry into cells? posted on 8:03 PM, May 12, 2020
 What does the role of ACE2 as a receptor for viral entry suggest regarding targeted therapy for COVID-19? posted on 8:33 PM, May 12, 2020
RSS rss

 

FAQs - NSAIDs and COVID-19

Updated: May 13, 2020
 Is there any evidence to suggest that regular use of NSAIDs increases the risk of infection or having a more severe course of complications from COVID-19? posted on 8:35 PM, May 12, 2020
 Can NSAIDs be used to treat myalgias and fever attributable to COVID-19? posted on 8:37 PM, May 12, 2020
 Is it safe to take NSAIDs for symptomatic treatment of fever and myalgias followning COVID-19 infection? posted on 8:45 PM, May 12, 2020
RSS rss

 

FAQs - Practical issues for patients taking ACEI or ARBs

Updated: May 13, 2020
 Should patients alter their use of ACEI or ARBs during the pandemic? posted on 8:48 PM, May 12, 2020
RSS rss

 

FAQs - Antiviral efficacy in treating COVID-19

Updated: May 13, 2020
 Is there sufficient evidence of antiviral medication effectiveness to prescribe one of these drugs for prevention or treatment of COVID-19? posted on 8:52 PM, May 12, 2020
RSS rss